+ 91-22-2418 1818

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

OUR PRODUCTS

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Ophthalmology

EYLEA® (aflibercept) Injection is a prescription medication administered by injection into the eye. You should not use EYLEA if you have an infection in or around the eye, eye pain or redness, or known allergies to any of the ingredients in EYLEA, including aflibercept. Macular Edema following Retinal Vein Occlusion (RVO): The recommended dose for EYLEA is 2 mg administered by injection in the eye monthly (every 4 weeks).

Eylea 2mg Injection

Eylea 2mg Injection

What is Eylea?
Eylea is a medicine that contains the active substance aflibercept. It is available as a solution for injection into the eye in pre-filled syringes or vials.


What is Eylea used for?
• The ‘wet’ form of age-related macular degeneration (AMD), a disease which affects the central part of the retina (called the macula) at the back of the eye. The wet form of AMD is caused by the abnormal growth of blood vessels under the macula, which may leak fluid and blood and cause swelling.
• Impaired vision due to macular oedema (swelling) that follows blockage of either the main vein carrying blood from the retina (known as central retinal vein occlusion, CRVO) or of smaller branch veins (known as branch retinal vein occlusion, BRVO).
• Impaired vision due to macular oedema associated with damage to blood vessels caused by diabetes. The macula provides central vision that is needed to see detail for everyday tasks such as driving, reading and recognizing faces. The diseases cause the gradual loss of the central part of a person’s vision.

Eylea 2mg Injection

Eylea 2mg Injection

COMPANY :- Bayer

MODE OF ACTION :- In wet macular degeneration, abnormal blood vessel grow in the choriocapillaris, a layer of capillaries in the eye, leading to blood and protein leakage below the macula. Tumours need blood vessels sprouting into them when they become larger than a few millimetres, in order to get access to oxygen and nutritive substances to facilitate further growth. Aflibercept binds to circulating VEGFs and acts like a "VEGF trap".[8] It thereby inhibits the activity of the vascular endothelial growth factor subtypes VEGF-A and VEGF-B, as well as to placental growth factor (PGF), inhibiting the growth of new blood vessels in the choriocapillaris or the tumour, respectively.[9] The aim of the cancer treatment, so to speak, is to starve the tumour. .

EYLEA is an anti-angiogenic with an innovative mode of action.

STRENGTH : - 2mg /0.5ml , 40mg /ml

List of excipients- Polysorbate 20
Sodium dihydrogen phosphate, monohydrate (for pH adjustment)
Disodium hydrogen phosphate, heptahydrate (for pH adjustment)
Sodium chloride
Sucrose
Water for injection

Side effects :-
• bloody eye
• blurred vision
• eye pain
• vision changes